Mehmet Karahan

Mehmet Karahan

Auto-generated profile, based on publicly available information

Mehmet Karahan

Department of Cardiovascular Surgery Ankara City Hospital Ankara Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in Revista Portuguesa de Cardiologia
Verified
Journal Article
Open access
MAMehmet Şahin Adıyaman
Mehmet Şahin Adıyaman
ÖAÖzlem Aba Adıyaman
Özlem Aba Adıyaman
ADAdile Ferda Dağlı
Adile Ferda Dağlı
MKMehmet Zülkif Karahan
Mehmet Zülkif Karahan
MDMustafa Necati Dağlı
Mustafa Necati Dağlı
Doxorubicin (DOX) is an anthracycline cytotoxic chemotherapeutic drug that is commonly used in cancer treatment. A major side effect limiting the clinical use of DOX is cardiotoxicity due to oxidative injury. Nigella sativa (NS) is an annual flowering plant with antioxidant properties. Its seeds contain several bioactive constituents such as saturated and unsaturated fatty acids, thymoquinone, dithymoquinone, thymohydroquinone, and thymol. In this study, we investigated the effect of NS extract on DOX-induced cardiotoxicity. The experimental study animals consisted of 28 male Sprague Dawley rats weighing between 300 and 400 g. Four study groups each of seven rats were defined: controls; NS extract; DOX; and DOX+NS. Control and DOX rats received standard food, while each rat in the NS and DOX+NS groups also received 100 mg/kg NS extract orally. At day 28 of follow-up, rats in the DOX groups were administered a single 10 mg/kg intraperitoneal dose of DOX, while rats in the control and NS groups received a single 10 mg/kg dose of physiological saline solution. All animals were monitored for 35 days. On day 35, the rats were decapitated and serum and cardiac tissue samples were obtained. Troponin and NT-proBNP levels were measured in blood sera, while malondialdehyde (MDA), nitric oxide, total antioxidant capacity (TAC), and total oxidative stress (TOS) levels were quantified in sera and tissue samples. Histological alterations that were assessed in cardiac tissue included myocyte disarray, small vessel disease, myocyte hypertrophy, and fibrosis. The DOX group had significantly higher NT-proBNP, TOS, and MDA, with greater histopathological derangement. TAC was significantly elevated in the DOX+NS group, which also exhibited significantly lower troponin, TOS, and MDA, as well as significantly higher TAC compared to the DOX group. Histopathological examination showed that the significant structural derangement observed in DOX rats was markedly and significantly reduced in DOX+NS rats. Our results suggest that NS extract may prevent DOX-induced cardiotoxicity and thus represents a promising cardioprotective agent.

1 June 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
MKMehmet Karahan
Mehmet Karahan
EAEmre Aygun
Emre Aygun
MPMustafa Pac
Mustafa Pac
OBJECTIVES: The aim of this study was to examine the haemodynamic effects of preoperative levosimendan infusion in patients who underwent left ventricular assist device implantation and evaluate the prognoses. METHODS: Between May 2013 and October 2018, 85 adult patients who underwent left ventricular assist device implantation were included; 44 and 41 patients suffered from dilated cardiomyopathy and ischaemic cardiomyopathy, respectively. Patients were divided into 2 groups: group A (58 patients) included those who received levosimendan infusion in addition to other inotropes and group B (27 patients) included those who received inotropic agents other than levosimendan. Levosimendan infusion was started at a dose of 0.1 µg⋅kg−1⋅min−1 for a maximum of 48 h without a bolus. The primary outcome was early right ventricular failure (RVF). The secondary outcomes were in-hospital mortality, need for right ventricular assist device, late RVF and recovery of end-organ functions. The safety end points of levosimendan included hypotension, atrial fibrillation, ventricular tachycardia or fibrillation and resuscitated cardiac arrest. RESULTS: Patient characteristics were similar in both groups. No significant differences between groups were observed in the rates of early mortality, RVF, need for right ventricular assist device, cardiopulmonary bypass time and intensive care unit stay. Survival rates at 30 days, 1 year and 3 years and freedom from late RVF were similar between the groups. Administration of levosimendan was safe, generally well-tolerated and not interrupted because of side effects. CONCLUSIONS: Levosimendan therapy was well-tolerated in patients who received permanent left ventricular assist devices. Combined preoperative therapy with inotropes and levosimendan significantly improves end-organ functions.

3 December 2019 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
MKMehmet Karahan
Mehmet Karahan
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
EAEmre Aygun
Emre Aygun
MPMustafa Pac
Mustafa Pac

1 April 2021 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
MKMehmet Karahan
Mehmet Karahan
EUErtekin Utku Unal
Ertekin Utku Unal
MPMustafa Pac
Mustafa Pac

1 January 2018 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
KÇKenan Çetin
Kenan Çetin
HSHasan Ediz Sikar
Hasan Ediz Sikar
AKAytaç Emre Kocaoğlu
Aytaç Emre Kocaoğlu
MKMuhammet Fikri Kündeş
Muhammet Fikri Kündeş
MKMehmet Karahan
Mehmet Karahan
LKLevent Kaptanoğlu
Levent Kaptanoğlu
Çetin K, et al. Ann Surg Treat Res. 2018 Feb;94(2):88-93. https://doi.org/10.4174/astr.2018.94.2.88

10 April 2023 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
SKSinan Sabit Kocabeyoglu
Sinan Sabit Kocabeyoglu
UKUmit Kervan
Umit Kervan
DSDogan Emre Sert
Dogan Emre Sert
MKMehmet Karahan
Mehmet Karahan
AKAhmet Vedat Kavurt
Ahmet Vedat Kavurt
SKSerhat Koca
Serhat Koca
Purpose: The aim of this study is to investigate the efficacy of adaptation of right ventricular (RV) risk scores used in adult patients to pediatric age group undergoing LVAD implantation. Methods: Twenty-two pediatric patients who underwent LVAD implantation were retrospectively reviewed from January 2014 to September 2018. Preoperative patient characteristics, hemodynamic parameters, and echocardiographic data were collected. Adult RV risk scores were calculated for all patients. Effects of all the parameters on RV function were also investigated. Study endpoints were RVF and in-hospital mortality. Results: Eleven (50%) of 22 patients were male. The mean age of the patients was 13.4 ± 3.8 years. The mean body surface area of the patients was 1.4 ± 0.4 m2. In five patients BiVAD implantation was performed. Of these five BiVAD patients two underwent successful heart transplant; two weaned from temporary RVAD and last patient died due to multi-organ failure. Four patients showed signs of early RVF; one patient was transplanted successfully while on medical support. Three patients developing RVF did not respond medical therapy necessitating ECMO and died in the early postoperative period. All risk scores and potential predictive factors were evaluated individually and in combination of several parameters. No significant predictor for RVF in pediatric patients that underwent LVAD implantation was found ( p > 0.05). Conclusion: Neither an adult risk score nor a predictive factor was successful in predicting RVF, alone or in combination due to limited number of patients and events. Large further investigations are needed to identify the predictors or scoring system in pediatric population.